Journal List > J Korean Ophthalmol Soc > v.55(4) > 1009941

Kim, Cho, Kyung, and Chang: Short-Term Clinical Outcomes of Laser Trabeculoplasty Using a 577-nm Wavelength Laser

Abstract

Purpose

To evaluate the pressure-lowering effects of single-spot laser trabeculoplasty and patterned laser trabeculoplasty using a 577-nm wavelength laser.

Methods

A total 35 eyes of 35 patients with primary open-angle glaucoma were enrolled in this study. Eighteen eyes of 18 patients were treated with 360° single-spot laser trabeculoplasty and 17 eyes of 17 patients were treated with 360° patterned laser trabeculoplasty. All patients were evaluated after laser trabeculoplasty at 1 week, 1 month, 3 months, and 6 months using slit lamp examination and Goldmann applanation tonometry.

Results

At 6 months postoperatively, the single-spot laser trabeculoplasty group had a mean IOP of 15.89 ± 3.89 mm Hg with a mean IOP reduction of 37.1%, while the patterned laser trabeculoplasty group had a mean IOP of 17.57 ± 2.64 mm Hg with a mean IOP reduction of 27.1%.

Conclusions

Laser trabeculoplasty with a 577-nm optically pumped semiconductor laser was safe and demonstrated an IOP lowering effect. There were no significant differences in the IOP lowering effects between the single-spot laser trabeculoplasty and the patterned laser trabeculoplasty.

References

1. Wise JB, Witter SL. Argon laser therapy for open-angle glaucoma. A pilot study. Arch Ophthalmol. 1979; 97:319–22.
2. Latina MA, Park C. Selective targeting of trabecular meshwork cells: in vitro studies of pulsed and CW laser interactions. Exp Eye Res. 1995; 60:359–71.
crossref
3. Cho BJ, Kim TW, Woo SJ, et al. Short-term clinical outcome of patterned scanning laser photocoagulation with short exposure time in diabetic retinopathy. J Korean Ophthalmol Soc. 2009; 50:376–82.
crossref
4. Turati M, Gil-Carrasco F, Morales A, et al. Patterned laser trabeculoplasty. Ophthalmic Surg Lasers Imaging. 2010; 41:538–45.
crossref
5. Hodapp E, Parrish RK II, Anderson DR. Clinical decisions in glaucoma. St. Louis: Mosby;1993. p. 52–61.
6. Wise JB. Glaucoma treatment by trabecular tightening with the argon laser. Int Ophthalmol Clin. 1981; 21:69–78.
crossref
7. Van Buskirk EM, Pond V, Rosenquist RC, Acott TS. Argon laser trabeculoplasty. Studies of mechanism of action. Ophthalmology. 1984; 91:1005–10.
8. Alvarado JA, Alvarado RG, Yeh RF, et al. A new insight into the cellular regulation of aqueous outflow: how trabecular meshwork endothelial cells drive a mechanism that regulates the permeability of Schlemm's canal endothelial cells. Br J Ophthalmol. 2005; 89:1500–5.
crossref
9. Bradley JM, Anderssohn AM, Colvis CM, et al. Mediation of laser trabeculoplasty-induced matrix metalloproteinase expression by IL-1beta and TNFalpha. Invest Ophthalmol Vis Sci. 2000; 41:422–30.
10. Samples JR, Singh K, Lin SC, et al. Laser trabeculoplasty for open-angle glaucoma: a report by the american academy of ophthalmology. Ophthalmology. 2011; 118:2296–302.
11. Worthen DM, Wickham MG. Laser trabeculotomy in monkeys. Invest Ophthalmol. 1973; 12:707–11.
12. Park JJ, LEE JW, Lee KW. Comparison of clinical outcomes of argon laser versus selective laser trabeculoplasty in POAG. J Korean Ophthalmol Soc. 2008; 49:1491–500.
crossref
13. Brancato R, Carassa R, Trabucchi G. Diode laser compared with argon laser for trabeculoplasty. Am J Ophthalmol. 1991; 112:50–5.
crossref
14. Chung PY, Schuman JS, Netland PA, et al. Five-year results of a randomized, prospective, clinical trial of diode vs argon laser trabeculoplasty for open-angle glaucoma. Am J Ophthalmol. 1998; 126:185–90.
crossref
15. Kramer TR, Noecker RJ. Comparison of the morphologic changes after selective laser trabeculoplasty and argon laser trabeculoplasty in human eye bank eyes. Ophthalmology. 2001; 108:773–9.
crossref
16. Allingham RR. Shields textbook of glaucoma. 6th ed.Wolters Kluwer: Lippincott Williams&Wlikins;2011. p. 455.
17. Jang YS, Kim JM, Lim TH, et al. Comparison of 180° and 360° selective laser trabeculoplasty. J Korean Ophthalmol Soc. 2012; 53:291–6.
crossref
18. Schuele G, Rumohr M, Huettmann G, Brinkmann R. RPE damage thresholds and mechanisms for laser exposure in the micro-second-to-milisecond time regimen. Invest Ophthalmol Vis Sci. 2005; 46:714–9.
19. Sramek CK, Leung LS, Paulus YM, Palanker DV. Therapeutic window of retinal photocoagulation with green (532-nm) and yellow (577-nm) lasers. Ophthalmic Surg Lasers Imaging. 2012; 43:341–7.
crossref

Figure 1.
Graphic user interface for patterned laser trabeculoplasty software.
jkos-55-563f1.tif
Figure 2.
Procedure of patterned laser trabeculoplasty. (A) Schematic view of patterned laser trabeculoplasty. Pattern of Aiming beam (635 nm) is projected on trabecular meshwork. Once a physician presses the foot pedal, PASCAL photo-coagulator delivers a patterned laser on trabecular meshwork. (B) After shooting the laser, the pattern is automatically ro-tated clockwise by 11.25˚. (C) Gonioscopic view of patterned laser trabeculoplasty.
jkos-55-563f2.tif
Figure 3.
Changes in mean intraocular pressure after laser trabeculoplasty. No statistical differences between the groups during follow-up (p > 0.05, Mann-Whitney test). SLT = single spot laser trabeculoplasty; PLT = patterned laser trabeculoplasty.
jkos-55-563f3.tif
Figure 4.
Kaplan-Meier survival curve using success defi-nition in single spot laser trabeculoplasty and patterned laser trabeculoplasty groups. No statistical differences between the groups during follow-up (p = 0.93). Cum = cumulative; SLT = single spot laser trabeculoplasty; PLT = patterned laser trabeculoplasty.
jkos-55-563f4.tif
Table 1.
Patient demographics
  Single spot laser group Patterned laser group p-value
Age (years) 53 ± 16.59 (19-72) 46 ± 9.5 (35-65) 0.30*
Sex :     0.87
  Male 10 8  
  Female 8 9  
Mean number of glaucoma medication (n, range) 0.81 ± 1.17 (0-3) 1.30 ± 1.25 (0-3) 0.44*
Baseline IOP (mm Hg, range) 25.27 ± 7.51 (18-32) 24.11 ± 4.17 (19-45) 0.91*
Mean duration of increased IOP (month) 2.44 ± 1.69 (1-5) 2.35 ± 1.59 (1-6) 0.64*
Degrees of glaucomatous visual field loss (month, range)     0.49
  Early defect 7 8  
  Moderate defect 5 5  
  Severe defect 4 6  

Values are presented as mean ± SD.

IOP = intraocular pressure.

* Mann-Whitney U-test

Chi-square test.

Table 2.
Changes of mean intraocular pressure during 6 months of follow-up
Time Single spot laser group
Patterned laser group
Number of eyes IOP (mm Hg) p-value* Number of eyes IOP (mm Hg) p-value*
Baseline 18 25.27 ± 7.51 (18-32)   17 24.11 ± 4.17 (19-45)  
1 week 18 18.09 ± 4.44 (12-25) 0.01 17 17.78 ± 2.49 (14-21) 0.01
1 month 16 19.44 ± 5.15 (10-26) 0.02 15 19.44 ± 5.15 (12-20) 0.03
3 months 16 17.67 ± 5.13 (11-23) 0.02 15 18.43 ± 1.40 (17-20) 0.02
6 months 18 15.89 ± 3.89 (11-21) 0.01 17 17.57 ± 2.64 (15-22) 0.03

Values are presented as mean ± SD.

* Wilcoxon signed ranks test.

Table 3.
Success rate of laser trabeculoplasty
  Success Failure
IOP decreased IOP increased
Single spot laser trabeculoplasty 50% (9) 44.44% (8) 5.56% (1)
Patterned laser trabeculoplasty 52.94% (9) 47.06% (8) 0% (0)
p-value* 0.87    

IOP = intraocular pressure.

* Chi-square test.

Table 4.
Mean IOP reduction of subgroups between single spot laser trabeculoplasty and patterned laser trabeculoplasty groups using success definitions
    Baseline IOP (mm Hg) IOP after 6 months (mm Hg) p-value*
SLT Success subgroup (n = 9) 27.40 ± 10.08 (19-45) 14.50 ± 2.88 (11-18) 0.01
  Failure subgroup (n = 9) 23.50 ± 3.45 (19-29) 17.00 ± 4.16 (11-21) 0.42
  p-value 0.03 0.16  
PLT Success subgroup (n = 9) 26.80 ± 3.27 (24-32) 17.50 ± 2.08 (15-20) 0.01
  Failure subgroup (n = 8) 20.75 ± 2.22 (18-23) 17.67 ± 3.79 (15-22) 0.06
  p-value 0.01 0.30  

Values are presented as mean ± SD.

IOP = intraocular pressure; SLT = single spot laser trabeculoplasty; PLT = patterned laser trabeculoplasty.

* Wilcoxon signed ranks test; † Mann-Whitney U-test.

TOOLS
Similar articles